Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab the...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Christian W., Ruck, Tobias, McHugh, Donal, Pfeuffer, Steffen, Gross, Catharina C., Korsukewitz, Catharina, Melzer, Nico, Klotz, Luisa, Meuth, Sven G., Münz, Christian, Nimmerjahn, Falk, Wiendl, Heinz, Lünemann, Jan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917309/
https://www.ncbi.nlm.nih.gov/pubmed/31682087
http://dx.doi.org/10.1002/acn3.50935
Descripción
Sumario:Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing‐remitting multiple sclerosis. No differences in clinical and MRI‐based efficacy parameters, the development of severe infusion‐associated reactions and secondary autoimmune diseases during a 2 year follow‐up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

Ejemplares similares